However, resembling the anti-PD-1 treatment, anti-PD-L1 has a superior effect in non-CNS solid cancers compared to GBM [149,150], and thus this strategy will most likely require a combinatory regimen to increase its efficacy for GBM patients. This evidence concerns the gene PDCD1 and glioblastoma.